GlassScriptPhysician profile
Jigish M Patel
NPI 1427026822
$5,698.90
in general payments reported to CMS, 2019-2025
31 companies · $887 in 2025
The $887 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $906 · 2021: $1,032 · 2022: $593 · 2023: $960 · 2024: $932 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,331.41 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $903.80 | 2020-2025 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $667.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $489.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $403.59 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $314.23 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.82 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $175.82 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $158.61 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $150.59 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Abbvie INC. | $146.90 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $127.31 | 2020-2023 | Livalo |
| Sanofi Pasteur INC. | $53.06 | 2019-2022 | |
| Amarin Pharma, INC. | $52.39 | 2019-2021 | |
| Allergan, INC. | $46.56 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.75 | 2020-2024 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $44.90 | 2024-2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $33.83 | 2021 | |
| Opsens INC. | $33.45 | 2019 | |
| Dexcom, INC. | $32.41 | 2024 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $28.12 | 2022 | |
| Horizon Therapeutics Plc | $21.71 | 2022 | |
| Sumitomo Pharma America, INC. | $20.98 | 2024 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $19.35 | 2022 | |
| Eisai INC. | $17.87 | 2020 | |
| Astellas Pharma US INC | $17.51 | 2023 | Veozah |
| Seqirus USA INC | $15.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.80 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.72 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.68 | 2024 | Quviviq |
| Medtronic, INC. | $13.31 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jigish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.